Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.17+0.06 (+0.43%)
Close on Oct 30, 2026Market cap $11.83BP/E 26.2Yield 0.59%
Earnings
Dr Reddys Laboratories's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q4 FY2019
₹40.17B
+13.6% on a year earlier
EPS, Q4 FY2019
26.16 INR
18.18 INR a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Dr Reddys Laboratories's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2019ended Mar 31, 2019 | May 17, 2019during market hours | ₹40.17B | +13.6% | 26.16 INR | Release |
| Q4 FY2018ended Mar 31, 2018 | May 22, 2018during market hours | ₹35.35B | – | 18.18 INR | Release |
| Q4 FY2017ended Mar 31, 2017 | May 15, 2017during market hours | – | – | – | Release |
| Q4 FY2016ended Mar 31, 2016 | May 13, 2016during market hours | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Dr Reddys Laboratories has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Dr Reddys Laboratories puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Dr Reddys Laboratories filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K